News | November 08, 2010

Report Gives New Insights for Improving Cardiac Care

November 8, 2010 – The American College of Cardiology (ACC) and American Heart Association (AHA) issued a joint report outlining new performance measures in cardiac care. The full report will be published in the Nov. 16 issue of the Journal of the American College of Cardiology.

“As performance measures have grown in importance, we must constantly be sure that they are created in the most sound scientific manner so that the goal of using these measures – to improve care – are most likely to be achieved,” said John A Spertus, M.D., MPH Daniel Lauer/Missouri Endowed Chair and professor, University of Missouri Kansas City and chair of the 12-person writing committee. “This document provides guidance to the creators of performance measures so that they can create the most useful measures to improve the quality of care.”

The inherent delay between the collection of new evidence and its adoption into routine care means performance measures do not always take emerging evidence into account. The updated report addresses this issue and ensures that only the processes of care associated with the strongest evidence and meaningful outcomes are endorsed, Spertus said.

“Professional societies have learned a lot about new challenges and opportunities since the original recommendations for the methodology of performance measure development were written five years ago,” he said. “Since performance measures, once developed, almost always become mandatory clinical actions, it is very important that the issues raised in this paper be considered so that adverse consequences can be avoided.”

Currently, performance measures are more often used as tools for accountability and reimbursement. Initially, they were intended to help physicians improve the quality of care and patient outcomes.

“As we use performance measures, we have learned how to make them more accurate, meaningful and actionable,” Spertus said. “Recently, insurers are starting to pay more for practices that more often comply with performance measures and major payers, such as Medicare, are increasingly publishing providers’ performance for the public to review.”

For more information: www.cardiosource.org


Related Content

News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Videos | Pharmaceuticals

In Part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based ...

Home September 11, 2023
Home
Videos | Pharmaceuticals

A 3-part video series with Christine E. Seidman, MD, FACC, FAHA In the first of this 3-part “One on One” series, Dr ...

Home August 28, 2023
Home
News | Pharmaceuticals

August 1, 2023 —LEXEO Therapeutics, a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based ...

Home August 01, 2023
Home
News | Pharmaceuticals

July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio ...

Home July 10, 2023
Home
Subscribe Now